25 results for «1532»
25 results
New technology for transcather valve replacement - LIVE case
25 Nov 2024 – From PCR London Valves 2024
Watch a series of recorded cases showcasing advanced valve therapies and innovative techniques:
- A 70-year-old man with Marfan syndrome (treated by Bentall and CABG in 2012), impaired LV function (35%), CRT-D, and symptomatic severe primary MR (A2 prolapse with calcification) underwent implantation of an Intrepid valve under...
Transcatheter primary mitral regurgitation repair and tricuspid replacement - LIVE case
28 Nov 2022 – From PCR London Valves 2022
- Part 1: Primary MR repair (recorded case)
An 89-year-old male with atrial fibrillation, severe primary MR (prolapse A1-A2) with a preserved LV function. The operators implant 1 Pascal ACE, on general anaesthesia, guided by TEE. - Part 2: Tricuspid valve in valve (Live case)
A 52-year-old female, with diabetes and...
EuroPCR 2023 Hotlines/Late-Breaking Trials: mitral and tricuspid valves disease
17 May 2023 – From EuroPCR 2023
The presenters share their views on a range of essays and studies. Join them for an update on: Early experience with a d-shape, monoleaflet TMVR system; Outcomes of Mitral Valve-in-Valve, Mitral Valve-in-Ring and Valve-in-Mitral Annular; Calcification: prospective MITRAL; DRAGONFLY-DMR: transcatheter repair by DragonFly device in mitral...
Coronary access and revascularisation in patients undergoing TAVI: from work-up to lifetime management
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the comprehensive management of ischemic heart disease in patients undergoing transcatheter aortic valve implantation (TAVI). It highlights the critical importance of maintaining coronary access post-TAVI and explores how various valve designs affect coronary accessibility, particularly in cases involving valve-in-valve (TAV-in-TAV) procedures, guiding...
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.
Author
Author
- ← previous
- 1
- 2
- next →